Literature DB >> 3508570

Assessment of variance in bioavailability studies: comments on the article by McNamara et al.

C M Metzler.   

Abstract

Mesh：

Year:  1987        PMID： 3508570     DOI： 10.1023/a:1016448110088

Source DB:  PubMed          Journal:  Pharm Res        ISSN： 0724-8741            Impact factor:   4.200


× No keyword cloud information.
  4 in total

1.  Assessment of 75/75 rule: FDA viewpoint.

Authors:  B E Cabana
Journal:  J Pharm Sci       Date:  1983-01       Impact factor: 3.534

2.  An aid to decision-making in bioequivalence assessment.

Authors:  H Fluehler; J Hirtz; H A Moser
Journal:  J Pharmacokinet Biopharm       Date:  1981-04

3.  Statistical simulation study of new proposed uniformity requirement for bioequivalency studies.

Authors:  J D Haynes
Journal:  J Pharm Sci       Date:  1981-06       Impact factor: 3.534

4.  Influence of tablet dissolution on furosemide bioavailability: a bioequivalence study.

Authors:  P J McNamara; T S Foster; G A Digenis; R B Patel; W A Craig; P G Welling; R S Rapaka; V K Prasad; V P Shah
Journal:  Pharm Res       Date:  1987-04       Impact factor: 4.200
  4 in total
  2 in total

Review 1.  Review of methods and criteria for the evaluation of bioequivalence studies.

Authors:  G Pabst; H Jaeger
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Reply to "Assessment of Variance in Bioavailability Studies: comments on the article by McNamara et al." by Carl M. Metzler.

Authors:  J P Skelly; V P Shah; D J Schuirmann
Journal:  Pharm Res       Date:  1988-05       Impact factor: 4.200
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.